Dispensing patterns for antidiabetic agents in New Zealand: are the guidelines being followed?

N Z Med J. 2017 Nov 10;130(1465):12-18.

Abstract

Aims: Type 2 diabetes mellitus (T2DM) is a significant public health issue in New Zealand. Effective management and glycaemic control is critical for reducing diabetes-related complications. Treatment guidelines are well established in New Zealand. Using dispensing data as a proxy for prescribing data, this paper aims to describe the pattern of first- and second-line antidiabetic agent (AA) dispensing for T2DM in New Zealand and assess adherence with treatment guidelines.

Methods: Analysis of national dispensing data for AA medications using the Pharmaceutical Collection database from 2007/08 to 2015/16.

Results: Metformin monotherapy remains the most commonly prescribed first-line T2DM medication prescribed, accounting for 85% of initial agents prescribed. Sulfonylureas are the most common second-line agents used, accounting for 70% of all second-line agents.

Conclusion: There is a high degree of adherence with the T2DM treatment guidelines in New Zealand.

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Medication Adherence / statistics & numerical data*
  • Metformin / therapeutic use
  • New Zealand

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Metformin